A novel histone deacetylase inhibitor reduces abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice

Research output: Contribution to journalArticleResearchpeer-review

44 Citations (Scopus)


Background/Aims: Aberrant expression of components of the matrix metalloproteinase (MMP) enzyme system is implicated in abdominal aortic aneurysm (AAA) formation. We aimed to investigate the influence of a novel histone deacetylase (HDAC) inhibitor (HDACi) metacept-1 (MCT-1), previously documented to reduce MMP expression, on HDAC activity and MMP expression in aortic smooth muscle cells and the in vivo incidence of AAAs. Methods: Western blot and gelatin zymography were used to determine HDAC activity and MMP-2 expression and activity in rat (rVSMCs) and human aortic vascular smooth muscle cells (hVSMCs) in vitro. In vivo AAAs were generated using apolipoprotein E-deficient mice infused with angiotensin (Ang) II. Immunohistochemistry detected MMP-2 and -9 expression in AAA tissue samples. Results: In vitro, MCT-1 inhibited HDAC activity in rVSMCs, and MMP-2 expression and proteolytic activity in hVSMCs.In vivo, Ang II treatment alone exhibited an AAA incidence of 84 . Doxycycline decreased the incidence of AAAs to 50 . Importantly, MCT-1 reduced AAA incidence to approximately 44 . MMP-2 and -9 immunoreactivity was reduced in MCT-1-treated aortic tissue. Conclusion: The novel HDACi MCT-1 inhibits MMP expressionand AAA incidence suggesting this compound may warrant further investigation in the context of AAA biology. Copyright (c) 2007 S. Karger AG, Basel.
Original languageEnglish
Pages (from-to)143 - 152
Number of pages10
JournalJournal of Vascular Research
Publication statusPublished - 2008

Cite this